author-photo

Tanya Granston

11

Papers

281

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial

2018 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (105)
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

2016 Blood
Show All
- Source
- Cite
- Save
Citations (33)
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

2015 Blood
Show All
- Source
- Cite
- Save
Citations (88)
Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)
PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)

2015 Haematologica
Show All
- Source
- Cite
- Save
Citations (1)
Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

2015 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Addressing Lagged Effects and Interval Censoring in the Stepped Wedge Design of Cluster Randomized Clinical Trials

2014
- Tanya Granston
Show All
- Source
- Cite
- Save
Citations (3)